BC
NVAX icon

Bayforest Capital’s Novavax NVAX Stock Holding History

Bayforest Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1K Sell
2,769
-5,095
-65% -$45.7K 0.02% 753
2026
Q1 		$64K Sell
7,864
-6,454
-45% -$58.5K 0.07% 500
2025
Q4 		$96.2K Buy
+14,318
New +$108K 0.07% 475
2025
Q3 		– Sell
-91,476
Closed -$576K – 863
2025
Q2 		$576K Buy
91,476
+28,493
+45% +$189K 0.25% 141
2025
Q1 		$404K Buy
+62,983
New +$521K 0.18% 217

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Bayforest Capital's NVAX Position: Q2 2026 in Review

Bayforest Capital reduced its Novavax (NVAX) stake by 65% in Q2 2026, selling an estimated $45.7K and leaving 2,769 shares worth $26.1K. The position accounts for 0.02% of the portfolio, ranked #753.

Bayforest Capital first reported a position in NVAX in Q1 2025 and has held it in 5 quarters since. The position peaked at $576K in Q2 2025. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Bayforest Capital held 2,769 shares of Novavax worth $26.1K as of Q2 2026.
  • Bayforest Capital sold 5,095 Novavax shares in Q2 2026, an estimated $45.7K.
  • Novavax made up 0.02% of Bayforest Capital's portfolio in Q2 2026, its #753 holding.
  • Bayforest Capital first reported a position in Novavax in Q1 2025 and has held it in 5 quarters since.
  • Bayforest Capital's Novavax position peaked at $576K in Q2 2025.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.